STEMCELL Technologies, Canada
Kimberly Snyder obtained her Master of Science in Experimental Medicine at the University of British Columbia in 2014. She completed her studies under the supervision of Dr. Kelly McNagny studying the role of the CD34-related sialomucin, podocalyxin in metastatic breast cancer. Furthermore, in a collaboration with the Centre for Drug Research and Development (CDRD), She used pre-clinical mouse models to evaluate candidate therapeutic antibodies against podocalyxin to block the growth and metastasis of established tumors. In 2014, Kim was recruited to STEMCELL Technologies Inc. and is a Scientist in R&D working in the Pluripotent Stem Cell Biology Team. Kim works on novel PSC media development for the maintenance of human pluripotent stem cells and has recently developed a new cGMP animal origin-free hPSC medium, TeSR™-AOF.
TOOLS FOR BASIC AND APPLIED STEM CELL BIOLOGY
Wednesday, June 11, 2025
2:00 PM – 3:30 PM HK Time